Aflibercept in epithelial ovarian carcinoma

被引：9

作者：

Moroney, John W. ^{[1
]}

Sood, Anil K. ^{[1
]}

Coleman, Robert L. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA

来源：

FUTURE ONCOLOGY | 2009年 / 5卷 / 05期

关键词：

aflibercept; antiangiogenesis; epithelial ovarian carcinoma; vascular endothelial growth factor; VEGF-Trap; ENDOTHELIAL GROWTH-FACTOR; GYNECOLOGIC-ONCOLOGY-GROUP; TYROSINE KINASE INHIBITOR; TUMOR-GROWTH; PHASE-II; FACTOR RECEPTORS; CANCER MODEL; VEGF-TRAP; ANGIOGENESIS; BEVACIZUMAB;

D O I：

10.2217/FON.09.35

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis is a hallmark of malignant transformation, With improved understanding of angiogenic signaling in both the normal and malignant state, there have been a number of agents developed that target VEGF signaling, These targeted agents can affect downstream VEGF signal transduction via unique mechanisms at different cellular and extracellular locations. The aflibercept, or VEGF-Trap, molecule is the subject of this article, Its molecular structure, pharmacokinetic and pharmacodynamic profile, and preclinical and early clinical data in epithelial ovarian carcinoma is reviewed. For comparison, other anti-angiogenic agents that have been or are currently being studied in epithelial ovarian carcinoma are also summarized. Finally, the anticipated role of aflibercept in the treatment of epithelial ovarian carcinoma is also discussed.

引用

页码：591 / 600

页数：10

共 37 条

[1]

BIAGI JJO, 2008, P AM SOC CLIN ONC AS

[2]

BOOKMAN MA, 2006, P AM SOC CLIN ONC AS

[3] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study [J].

Burger, Robert A. ;

Sill, Michael W. ;

Monk, Bradley J. ;

Greer, Benjamin E. ;

Sorosky, Joel I. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5165-5171

[4]

Byrne AT, 2003, CLIN CANCER RES, V9, P5721

[5] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [J].

Cannistra, Stephen A. ;

Matulonis, Ursula A. ;

Penson, Richard T. ;

Hambleton, Julie ;

Dupont, Jakob ;

Mackey, Howard ;

Douglas, Jeffrey ;

Burger, Robert A. ;

Armstrong, Deborah ;

Wenham, Robert ;

McGuire, William .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5180-5186

[6] Conditional survival in ovarian cancer: Results from the SEER dataset 1988-2001 [J].

Choi, Mehee ;

Fuller, Clifton D. ;

Thomas, Charles R., Jr. ;

Wang, Samuel J. .

GYNECOLOGIC ONCOLOGY, 2008, 109 (02) :203-209

[7]

COLEMAN RL, 2008, P AM SOC CLIN ONC AS

[8]

COLOMBO N, 2008, P AM SOC CLIN ONC AS

[9] VEGF-targeted therapy: mechanisms of anti-tumour activity [J].

Ellis, Lee M. ;

Hicklin, Daniel J. .

NATURE REVIEWS CANCER, 2008, 8 (08) :579-591

[10]

FREYER G, 2008, P AM SOC CLIN ONC AS

← 1 2 3 4 →